NCT00369889View on ClinicalTrials.gov

A Study to Test the Safety and Efficacy of Erlotinib Plus Bevacizumab to Treat Advanced Thymoma and Thymic Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

18

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

September 30, 2007

Study Completion Date

September 30, 2007

Conditions

Thymic CancerThymoma

Interventions

DRUG

bevacizumab

iv every 21 days

DRUG

Erlotinib

oral daily

Trial Locations (1)

46202

Indiana University Cancer Center, Indianapolis

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

Indiana University School of Medicine

OTHER